Rapid-acting insulin analogues in basal-bolus regimens in type 1 diabetes mellitus

Endocrine Practice

Volumn 16, Issue 3, 2010, Pages 486-505

  Garg, Satish ^a   Ampudia Blasco, Francisco Javier ^b   Pfohl, Martin ^c  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c Evangelisches Bethesda Johanniter Klinikum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; PRAMLINTIDE; ANTIDIABETIC AGENT; BASAL INSULIN; DRUG DERIVATIVE; INSULIN;

BOLUS INJECTION; DIABETIC PATIENT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN TREATMENT; MEAL; MEDLINE; OBSERVATIONAL STUDY; POSTPRANDIAL STATE; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; FEMALE;

DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PREGNANCY;

EID: 77956637560     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP09294.RA     Document Type: Review

References (57)

1. Daneman D. Type 1 diabetes. Lancet. 2006;367:847-858. (Pubitemid 43363372)
2. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet. 2001;358:739-746. (Pubitemid 32823407)
3. Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: Recent developments. BMJ. 2004;328:750-754. (Pubitemid 38406430)
4. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381-389.
5. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653. (Pubitemid 41817713)
6. Ulrich H, Snyder B, Garg SK. Combining insulins for optimal blood glucose control in type I and 2 diabetes: Focus on insulin glulisine. Vasc Health Risk Manag. 2007;3:245-254. (Pubitemid 47214970)
7. Overmann H, Heinemann L. Injection-meal interval: Recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract. 1999;43:137-142.
8. Ashwell SG, Amiel SA, Bilous RW, et al. Improved glycaemic control with insulin glargine plus insulin lispro: A multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med. 2006;23:285-292.
9. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47:622-629. (Pubitemid 38658363)
10. Ashwell SG, Bradley C, Stephens JW, Witthaus E, Home PD. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in people with type 1 diabetes. Diabetes Care. 2008;31:1112-1117.
11. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006;19:CD003287.
12. Philotheou A, Arslanian S, Blatniczky L, Peterkova V, Souhami E, Danne T. Efficacy and safety of insulin glulisine versus insulin lispro as part of a basal-bolus insulin regimen in children and adolescents with type 1 diabetes mellitus. Diabetologia. 2008;51:S382 [Abstract 950].
13. Ludvigsson J, Mersebach H, Kanc Hanzel K, Holmberg H. Treatment with insulin aspart versus human insulin in children and adolescents with newly diagnosed type 1 diabetes. Diabetologia. 2007;50:S380 [Abstract 0921].
14. Brunetti P, Muggeo M, Cattin L, et al. Incidence of severe nocturnal hypoglycemia in patients with type 1 diabetes treated with insulin lispro or regular human insulin in addition to basal insulin glargine. Nutr Metab Cardiovasc Dis. 2009 Aug 22 [Epub ahead of print]
15. Kawamori R, Kadowaki T, Ishii H, Iwasaki M, Iwamoto Y. Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus. Diabetes Obes Metab. 2009;11:891-899.
16. Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: A double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med. 2004;21:769-775. (Pubitemid 38916224)
17. Home PD, Hallgren P, Usadel KH, et al. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes. Diabetes Res Clin Pract. 2006;71:131-139. (Pubitemid 43112104)
18. Home PD, Lindholm A, Riis A; European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: A randomized controlled trial. Diabet Med. 2000;17:762-770.
19. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000;23:583-588. (Pubitemid 30321534)
20. Tamás G, Marre M, Astorga R, Dedov I, Jacobsen J, Lindholm A; Insulin Aspart Study Goup. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Res Clin Pract. 2001;54:105-114.
21. Garg SK, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: Insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract. 2005;11:11-17. (Pubitemid 43073084)
22. Dreyer M, Prager R, Robinson A, et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res. 2005;37:702-707. (Pubitemid 41810494)
23. Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes. 1997;46:265-270.
24. Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. Clin Ther. 1997;19:62-72.
25. Annuzzi G, Del Prato S, Arcari R, et al. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: A multicenter randomized crossover trial. Nutr Metab Cardiovasc Dis. 2001;11:168-175. (Pubitemid 33686561)
26. Colombel A, Murat A, Krempf M, Kuchly-Anton B, Charbonnel B. Improvement of blood glucose control in type 1 diabetic patients treated with lispro and multiple NPH injections. Diabet Med. 1999;16:319-324.
27. Del Sindaco P, Ciofetta M, Lalli C, et al. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: Importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med. 1998;15:592-600. (Pubitemid 28319942)
28. Gale EA. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabet Med. 2000;17:209-214.
29. Heller SR, Amiel SA, Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. Diabetes Care. 1999;22:1607-1611.
30. Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson JH. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care. 1997;20:1827-1832.
31. Pfützner A, Küstner E, Forst T, et al. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes. 1996;104:25-30. (Pubitemid 26037141)
32. Recasens M, Aguilera E, Morinigo R, et al. Insulin lispro is as effective as regular insulin in optimising metabolic control and preserving beta-cell function at onset of type 1 diabetes mellitus. Diabetes Res Clin Pract. 2003;60:153-159. (Pubitemid 36561616)
33. Vignati L, Anderson JH Jr, Iversen PW. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Clin Ther. 1997;19:1408-1421.
34. Danne T, Råstam J, Odendahl R, et al. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes. Pediatr Diabetes. 2007;8:278-285. (Pubitemid 47422901)
35. Deeb LC, Holcombe JH, Brunelle R, et al. Insulin lispro lowers postprandial glucose in prepubertal children with diabetes. Pediatrics. 2001;108:1175-1179. (Pubitemid 33021195)
36. Fairchild JM, Ambler GR, Genoud-Lawton CH, et al. Insulin lispro versus regular insulin in children with type 1 diabetes on twice daily insulin. Pediatr Diabetes. 2000;1:135-141.
37. Ford-Adams ME, Murphy NP, Moore EJ, et al. Insulin lispro: A potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus. Diabet Med. 2003;20:656-660. (Pubitemid 36966561)
38. Garg SK, Carmain JA, Braddy KC, et al. Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes. Diabet Med. 1996;13:47-52. (Pubitemid 26046596)
39. Holcombe JH, Zalani S, Arora VK, Mast CJ. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther. 2002;24:629-638. (Pubitemid 34492884)
40. Becker RH, Frick AD, Nosek L, Heinemann L, Rave K. Dose-response relationship of insulin glulisine in subjects with type 1 diabetes. Diabetes Care. 2007;30:2506-2507.
41. Heise T, Nosek L, Spitzer H, et al. Insulin glulisine: A faster onset of action compared with insulin lispro. Diabetes Obes Metab. 2007;9:746-753. (Pubitemid 47261856)
42. Rave K, Klein O, Frick AD, Becker RH. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care. 2006;29:1812-1817. (Pubitemid 44156635)
43. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23:644-649.
44. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142-2148.
45. Porcellati F, Rossetti P, Busciantella NR, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: A double-blind, randomized, crossover study. Diabetes Care. 2007;30:2447-2452. (Pubitemid 47547770)
46. Porcellati F, Rossetti P, Ricci NB, et al. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. Diabetes Care. 2007;30:1261-1263. (Pubitemid 46684657)
47. Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: Assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia. 2005;48:1988-1995.
48. Becker RH. Insulin glulisine complementing basal insulins: A review of structure and activity. Diabetes Technol Ther. 2007;9:109-121.
49. Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet. 2008;47:7-20. (Pubitemid 350260885)
50. Schernthaner G, Wein W, Shnawa N, Bates PC, Birkett MA. Preprandial vs. postprandial insulin lispro-a comparative crossover trial in patients with type 1 diabetes. Diabet Med. 2004;21:279-284. (Pubitemid 38299624)
51. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA; Orals Plus Apidra and LANTUS (OPAL) study group. Introducing a simplified approach to insulin therapy in type 2 diabetes: A comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab. 2008;10:1178-1185.
52. Monnier L, Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: Indications and modalities. Diabetes Metab. 2006;32:7-13. (Pubitemid 43872590)
53. Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough - What next? Diabetes Metab Res Rev. 2007;23:257-264.
54. Lalli C, Ciofetta M, Del Sindaco P, et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care. 1999;22:468-477. (Pubitemid 29106907)
55. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T. Insulin lispro in CSII: Results of a double-blind crossover study. Diabetes. 1997;46:440-443. (Pubitemid 27090273)
56. Renner R, Pfützner A, Trautmann M, Harzer O, Sauter K, Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care. 1999;22:784-788.
57. Raskin P, Holcombe JH, Tamborlane WV, et al. A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. J Diabetes Complications. 2001;15:295-300. (Pubitemid 33065671)